Galbraith Kenneth

Chair & CEO

Galbraith Kenneth has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jan 12, 2026.

On the most recent filing, Galbraith Kenneth is listed as Chair & CEO at Zymeworks Inc. Inside the rolling window, Galbraith Kenneth reported no open-market purchases and 3 open-market sales totaling $3.3M in ZYME. The largest disclosed transaction in the window is a sale of 54,343 ZYME shares on Jan 5, 2026, worth $1.4M.

Companies traded

Other insiders at ZYME

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$3.3M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ZYMESale$690KJan 12SEC ↗
ZYMESale$1.4MJan 5SEC ↗
ZYMESale$1.3MDec 22SEC ↗
Showing 1–3 of 3
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Galbraith Kenneth made?

Galbraith Kenneth has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2025.

Which companies does Galbraith Kenneth trade?

Galbraith Kenneth has filed SEC Form 4 disclosures for 1 company, including ZYME.

When was Galbraith Kenneth's most recent SEC Form 4 filing?

Galbraith Kenneth's most recent SEC Form 4 filing on Tracefour is dated Jan 12, 2026.

What is Galbraith Kenneth's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Galbraith Kenneth is listed as Chair & CEO.

What is Galbraith Kenneth's total buy and sell value in the current window?

Inside the rolling retention window, Galbraith Kenneth bought $0 and sold $3.3M based on SEC Form 4 filings.

What was Galbraith Kenneth's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 54,343 ZYME shares on 2026-01-05, worth $1.4M, per SEC Form 4 filings.